R-CHOP resistance in diffuse large B-cell lymphoma: biological and molecular mechanisms

Although the first-line rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone regimen (R-CHOP) substantially improved outcomes for patients with diffuse large B-cell lymphoma (DLBCL), 40% of the patients suffered from relapsed/refractory disease and had poor survival outcomes. Th...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Liang, Li, Lin-Rong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2021
Materias:
Review Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7846449/
https://www.ncbi.nlm.nih.gov/pubmed/33323828
http://dx.doi.org/10.1097/CM9.0000000000001294

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7846449/
https://www.ncbi.nlm.nih.gov/pubmed/33323828
http://dx.doi.org/10.1097/CM9.0000000000001294

Ejemplares similares